Insulin production could move offshore

Price controls mandated by the Inflation Reduction Act could lead to insulin production being moved offshore if the discounts imposed on manufacturers cause margins to fall below cost. 

Announced Aug. 15, the prices for the first set of IRA-negotiated drugs included a maximum fair price  (MFP) of $119 for a 30-day supply of insulin aspart, a product sold by  Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) under various brand names including Fiasp, NovoLog, FlexTouch and NovoRapid. ...